Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

The SPR System utilizes Surface Plasmon Resonance ("SPR") technology, a leading biosensor technology in molecular biology. SPR technology has been successfully used for the analysis of proteins, nucleic acids and viruses for the past 20 years and has become a powerful platform for life sciences, drug discovery, medicine and food safety. Human papillomavirus ("HPV"), a common virus that infects the skin and mucous membranes of humans and causes various kinds of warts as well as cervical cancer, can be detected by adding pathological samples on the HPV-DNA biosensor chip (the "HPV-DNA chip") and analyzing the HPV-DNA chip with the SPR System. The SPR System is label-free with high throughput, high speed and a high degree of automation. The detection results can be displayed on a real-time and online basis. The SPR System can be used in various potential clinical diagnostic applications, such as the detection of biomarkers related to infectious diseases, cancers, cardiovascular disorders and immune system disorders.

"We are pleased to receive the SFDA approval for our SPR System on a timely basis," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company. "We have commenced the delivery of our SPR Systems to our large hospital customers and believe that more and more women will benefit from the use of our SPR system and HPV-DNA chips together with our cervical cancer FISH probes, both of which can guide physicians to determine and apply effective treatment in the early stages of cervical diseases to reduce the risk of cervical cancer as well as early detection of cervical cancer."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Patent issued for Concarlo-developed therapeutic peptide to treat drug-resistant breast cancer